A precystectomy decision model to predict pathological upstaging and oncological outcomes in clinical stage T2 bladder cancer

BJU International

Volumn 111, Issue 2, 2013, Pages 240-248

  Mitra, Anirban P ^a   Skinner, Eila C ^b   Miranda, Gus ^b   Daneshmand, Siamak ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

cT2 bladder cancer; decision tree; early cystectomy; neoadjuvant chemotherapy; pathological upstaging

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BLADDER CANCER; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CYSTECTOMY; DECISION TREE; FEMALE; HUMAN; HYDRONEPHROSIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TUMOR GROWTH; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; DECISION SUPPORT SYSTEMS, CLINICAL; DECISION TREES; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; HYDRONEPHROSIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84873184742     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11424.x     Document Type: Article

References (29)

1. Freeman JA, Esrig D, Stein JP, et al. Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer 1995; 76: 833-839
2. Shariat SF, Palapattu GS, Karakiewicz PI, et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 2007; 51: 137-149
3. Clark PE., Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer. Expert Rev Anticancer Ther 2009; 9: 821-830
4. Sonpavde G, Sternberg CN,. Neoadjuvant systemic therapy for urological malignancies. BJU Int 2010; 106: 6-22
5. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349: 859-866
6. International Collaboration of Trialists. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 1999; 354: 533-540
7. Sternberg CN, Donat SM, Bellmunt J, et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 2007; 69: 62-79
8. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003; 361: 1927-1934
9. Sonpavde G, Khan MM, Svatek RS, et al. Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. BJU Int 2011; 108: 687-692
10. Pasin E, Josephson DY, Mitra AP, Cote RJ, Stein JP,. Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol 2008; 10: 31-43
11. Quek ML, Stein JP, Nichols PW, et al. Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. J Urol 2005; 174: 103-106
12. Haleblian GE, Skinner EC, Dickinson MG, Lieskovsky G, Boyd SD, Skinner DG,. Hydronephrosis as a prognostic indicator in bladder cancer patients. J Urol 1998; 160: 2011-2014
13. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19: 666-675
14. Urinary bladder. In, Greene FL, Page DL, Fleming ID, et al. eds, AJCC Cancer Staging Manual, 6 edn. New York, NY: Springer-Verlag, 2002: 335-340
15. Mostofi FK, Sobin HL, Torlini H,. Histologic Typing of Urinary Bladder Tumors. Geneva: World Health Organization, 1973
16. Biggs D, de Ville B, Suen E., A method of choosing multiway partitions for classification and decision trees. J Appl Stat 1991; 18: 49-62
17. Niegisch G, Albers P,. Which patients benefit the most from neoadjuvant chemotherapy in advanced bladder cancer? Curr Opin Urol 2011; 21: 434-439
18. Sturgeon SR, Hartge P, Silverman DT, et al. Associations between bladder cancer risk factors and tumor stage and grade at diagnosis. Epidemiology 1994; 5: 218-225
19. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49: 466-5
20. Bochner BH, Kattan MW, Vora KC,. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 2006; 24: 3967-3972
21. Vickers AJ, Cronin AM, Kattan MW, et al. Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach. Cancer 2009; 115: 5460-5469
22. Shariat SF, Karakiewicz PI, Palapattu GS, et al. Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res 2006; 12: 6663-6676
23. Bartsch GC, Kuefer R, Gschwend JE, de, Petriconi R, Hautmann RE, Volkmer BG., Hydronephrosis as a prognostic marker in bladder cancer in a cystectomy-only series. Eur Urol 2007; 51: 690-697
24. Mitra AP, Datar RH, Cote RJ,. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol 2006; 24: 5552-5564
25. Nielsen ME, Shariat SF, Karakiewicz PI, et al. Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol 2007; 51: 699-706
26. Yu RJ, Stein JP, Cai J, Miranda G, Groshen S, Skinner DG. Superficial, (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy. J Urol 2006; 176: 493-498
27. Cheng L, Neumann RM, Scherer BG, et al. Tumor size predicts the survival of patients with pathologic stage T2 bladder carcinoma: a critical evaluation of the depth of muscle invasion. Cancer 1999; 85: 2638-2647
28. Boudreaux KJ Jr, Clark PE, Lowrance WT, et al. Comparison of American Joint Committee on Cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer. J Urol 2009; 181: 540-545
29. Gakis G, Schilling D, Renninger M, Seibold J, Sievert KD, Stenzl A,. Comparison of the new American Joint Committee on Cancer substratification in node-negative pT2 urothelial carcinoma of the bladder: analysis of patient outcomes in a contemporary series. BJU Int 2011; 107: 919-923